Role of AT1 receptors in permeability of the blood-brain barrier in diabetic hypertensive rats

Vascular Pharmacology

Volumn 45, Issue 3, 2006, Pages 141-147

  Awad, Azza S ^a  

^a Al Azhar University   (Egypt)

Author keywords

Blood brain barrier; Candesartan; Evans blue; Hypertension; l NAME; Streptozotocin

Indexed keywords

ADRENALIN; ALBUMIN; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; DRINKING WATER; EVANS BLUE; N(G) NITROARGININE METHYL ESTER; STREPTOZOCIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BENZIMIDAZOLE DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; GLUTATHIONE; SUPEROXIDE DISMUTASE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN TISSUE; CONTROLLED STUDY; DECAPITATION; DIABETIC HYPERTENSION; DRUG EFFECT; ENDOTHELIUM; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD PRESSURE; BRAIN; CAPILLARY PERMEABILITY; CHEMICALLY INDUCED DISORDER; EXPERIMENTAL DIABETES MELLITUS; HYPERTENSION; LIPID PEROXIDATION; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIOXIDANTS; BENZIMIDAZOLES; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD-BRAIN BARRIER; BODY WEIGHT; BRAIN; CAPILLARY PERMEABILITY; DIABETES MELLITUS, EXPERIMENTAL; EPINEPHRINE; EVANS BLUE; GLUTATHIONE; HYPERTENSION; INDICATORS AND REAGENTS; LIPID PEROXIDATION; MALE; NG-NITROARGININE METHYL ESTER; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; SUPEROXIDE DISMUTASE; TETRAZOLES; TIME FACTORS;

EID: 33750800366     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.04.004     Document Type: Article

References (67)

1. Akirav E.M., Chan O., Inouye K., Riddell M.C., Matthews S.G., and Vranic M. Partial leptin restoration increases hypothalamic-pituitary-adrenal activity while diminishing weight loss and hyperphagia in streptozotocin diabetic rats. Metabolism 53 12 (2004) 1558-1564
2. Albrecht E.W., Stegeman C.A., Heeringa P., Henning R.H., and VanGoor H. Protective role of endothelial nitric oxide synthase. J. Pathol. 199 1 (2003) 8-17
3. Alexander R.W. Theodore Cooper Memorial Lecture: hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension (1995) 155-161
4. Asiedu-Gyekye I.J., and Antwi D.A. Does losartan prevent cerebral edema? A preliminary study using a vascular compartment model. Med. Sci. 9 (2003) BR127-BR130
5. Baird T.A., Parsons M.W., Barber P.A., Butcher K.S., Desmond P.M., Tress B.M., Colman P.G., Jerums G., Chambers B.R., and Davis S.M. The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. J. Clin. Neurosci. 9 (2002) 618-626
6. Beutler E., Durom O., and Kelly B.M. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 1 61 (1963) 882-888
7. Brands M.W., and Fitzgerald S.M. Arterial pressure control at the onset of type I diabetes: the role of nitric oxide and the renin-angiotensin system. Am. J. Hypertens. 14 6pt2 (2001) 126S-131S
8. Bravata D.M., Kim N., Concato J., and Brass L.M. Hyperglycaemia in patients with acute ischaemic stroke: how often do we screen for undiagnosed diabetes?. QJM 96 (2003) 491-497
9. Busse R., Mulsch A., Fleming I., and Hecker M. Mechanism of nitric oxide release from the vascular endothelium. Circulation 87 (1993) V18-V25
10. Chan N.N., Vallance P., and Colhoun H.M. Nitric oxide and vascular responses in type I diabetes. Diabetologia 43 2 (2000) 137-147
11. Conteras F., Rivera M., Vasquez J., De La M.A., and Velasco M. Diabetes and hypertension physiopathology and therapeutics. J. Hum. Hypertens. 1 (2000) S26-S31
12. Cooper M.E., Allen T.J., Macmillar P., Bach L., Jerums G., and Doyle A.E. Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat. Am. J. Hypertens. 1 (1988) 5-10
13. Cosentino F., Hishikawa K., Katusic Z.S., and Luscher T.F. High glucose increase nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 96 (1997) 25-28
14. Dabros W., Dziga D., and Kordowiak A.M. The influence of BMOV [bis(maltolato)oxovanadium(IV)] on biochemical and morphological alterations characteristic for streptozotocin-diabetic rat liver Golgi complexes. Pol. J. Pathol. 53 4 (2002) 205-213
15. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
16. Dai W.J., Funk A., Herdegen T., Unger T., and Culman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 30 (1999) 2391-2398 discussion 2398-2399
17. Dalal P.M., and Parab P.V. Cerebrovascular disease in type 2 diabetes mellitus. Neurol. India 50 (2002) 380-385
18. Davidoff A.J., Pinault F.M., and Rodgers R.L. Ventricular relaxation of diabetic spontaneously hypertensive rat. Hypertension (Dallas) 15 (1990) 643-651
19. Desideri G., Bravi M.C., Tucci M., Croce G., Marinucci M.C., Santucci A., Alesse E., and Ferri C. Angiotensin II inhibits endothelial cell motility through an AT1-dependent oxidant-sensitive decrement of nitric oxide availability. Arterioscler. Thromb. Vasc. Biol. 1;23 7 (2003) 1218-1223
20. Dohi Y., Ohashi M., Sugiyama M., Takase H., Sato K., and Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens. Res. 26 9 (2003) 691-697
21. Engelhorn T., Goerike S., Doerfler A., Okorn C., Forsting M., Heusch G., et al. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 24 (2004) 467-474
22. Feillet-Coudray C., Rock E., Coudray C., Grzelkowska K.P., Azais-Braesco V., Dardevet D., and Mazur A. Lipid peroxidation and antioxidant status in experimental diabetes. Clin. Chim. Acta 284 (1999) 31-43
23. Gisselsson L., Smith M.L., and Siesjo B.K. Hyperglycemia and focal brain ischemia. J. Cereb. Blood Flow Metab. 19 (1999) 288-297
24. Goehkle P., Linz W., Sckolkens B.A., Wiemer G., and Unger T. Cardiac and vascular effect of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 28 (1996) 397-402
25. Griendling K.K., and Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin. Regul. Pept. 91 (2000) 21-27
26. Groth W., Blume A., Gohlke P., Unger T., and Culman J. Chronic pretreatment with candesartan improvery from focal cerebral ischaemia in rats. J. Hypertens. 21 11 (2003) 2175-2182
27. Hammes H.P., Brownlee M., Edelstein D., Saleck M., Martin S., and Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37 (1994) 32-35
28. Hanna I.R., Tanijama Y., Szocs K., Rocic P., and Griendling K.K. NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid. Redox Signal. 4 (2002) 899-914
29. Honing M.L., Morrison P.J., Banga J.D., Stroes E.S., and Rabelink T.J. Nitric oxide availability in diabetes mellitus. Diabetes Metab. Rev. 14 3 (1998) 241-249
30. Ito H., Takemori K., Kawai J., and Suzuki T. AT1 receptor antagonist prevents brain edema without lowering blood pressure. Acta Neurochir. Suppl. (wien) 76 (2000) 141-145
31. Johansson B.B. Hypertension. In: Pardridge W.M. (Ed). The Introduction to the Blood-Brain Barrier. Methodology, Biology and Pathology (1998), Cambridge University Press, Cambridge 427-433
32. Kagansky N., Levy S., and Knobler H. The role of hyperglycemia in acute stroke. Arch. Neurol. 58 (2001) 1209-1212
33. Kaya M., Kalayci R., Küçük M., Arican N., and Elmas I. Effect of losartan on the blood-brain barrier permeability in diabetic hypertensive rats. Life Sci. 73 25 (2003) 3235-3244
34. Koo J.R., and Vaziri N.D. Effects of diabetes, insulin and antioxidants on NO synthase abundance and NO interaction with reactive oxygen species. Kidney Int. 63 1 (2003) 195-201
35. Kusaka I., Kusaka G., Zhou C., Ishikawa M., Nanda A., Grager D.N., Zhang J.H., and Tang J. Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. Am. J. Physiol. 286 (2004) H2442-H2451
36. Lippoldt A., Kniesel U., Liebner S., Kalbacher H., Kirsch T., Wolburg H., and Haller H. Structural alterations of tight junctions are associated with loss of polarity in stroke-prone spontaneously hypertensive rat blood-brain barrier endothelial cells. Brain Res. 885 2 (2000) 251-261
37. Lorenzi M., Healy D.P., Hawkins R., Printz J.M., and Printz M.P. Studies on the permeability of the blood-brain barrier in experimental diabetes. Diabetologia 29 1 (1986) 58-62
38. Maeso R., Navarro-Cid J., Munoz-Garcia R., Rodrigo E., Ruilope L.M., and Laheral V. Losartan reduces phenylephrine constrictor response in aortic rings from SHR: role of NO and AT2 receptor. Hypertension 28 6 (1996) 967-972
39. Marklund S.L. Product of extracellular-superoxide dismutase catalysis. FEBS Lett. 184 2 (1985) 237-239 May 20
40. Marry J., and McLay J. Drug treatment of hypertension complicating diabetes mellitus. Drugs 56 2 (1998) 189-202
41. Mikawa S., Kinouchi H., Kamii H., Gobbell G.T., Chen S.F., Carlson E., Epstein C.J., and Chan P.H. Attenuation of acute and chronic damage following traumatic brain injury in copper, zinc-superoxide dismutase transgenic mice. J. Neurosurg. 85 (1996) 885-891
42. Mooradian A.D. Central nervous system complications of diabetes mellitus-a perspective from the blood-brain barrier. Brain Res. Rev. 23 3 (1997) 210-218
43. Maxwell A.J. Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. Nitric Oxide 6 (2002) 101-124
44. Namkoong C., Kim M.S., Jang P.G., Han S.M., Park H.S., Koh E.H., Lee W.J., Kim J.Y., Park I.S., Park J.Y., and Lee K.U. Enhanced hypothalamic AMP-activated protein kinase activity contributes to hyperphagia in diabetic rats. Diabetes 54 1 (2005) 63-68
45. Nickenig G., and Harrison D.G. The AT1-type angiotensin receptor in oxidative stress and atherogenesis: Part I. Oxidative stress and parthenogenesis. Circulation 105 (2002) 393-396
46. Nishimura Y., Ito T., and Saavedra J.M. Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 31 (2000) 2478-2486
47. Phillips M.I., and Sumners C. Angiotensin II in central nervous system physiology. Regul. Pept. 78 (1998) 1-11
48. Podar T., and Tuomilehto J. The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications. Aaaadrugs 62 (2002) 2007-2012
49. Privratsky J.R., Wold L.E., Sowers J.R., Quinn M.T., and Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NAD(P)H oxidase. Hypertension 42 (2003) 206-212
50. Ravi K., Ramachandran B., and Subramanian S. Effect of Eugenia Jambolana seed on antioxidant defense system in streptozotocin-induced diabetes in rats. Life Sci. 75 (2004) 2717-2731
51. Salameh A., Zinn M., and Dhein S. High d-glucose induces alterations of endothelial cell structure in a cell culture model. J. Cardiovasc. Pharmacol. 30 (1997) 182-190
52. Sasamura H., Shimizu-Hirota R., Nakaya H., and Saruta T. Effects of AT1 receptor antagonist on proteoglycan gene expression in hypertensive rats. Hypertens. Res. 24 2 (2001) 165
53. Schnackenberg C.G. Oxygen radicals in cardiovascular-renal disease. Curr. Opin. Pharmacol. 2 (2002) 121-125
54. Schiffrin E.L., and Touyz R.M. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J. Am. Coll. Cardiol. 42 5 (2003) 911-913
55. Sever P. Study on cognition and prognosis in the elderly. J. Renin Angiotensin Aldosterone Syst. vol. 3 (2002) 61-62
56. Sharifi A.M., Mousavi S.H., and Larijani B. Study of interaction between nitric oxide and ACE activity in STZ-induced diabetic rats: role of insulin. Pharmacol. Res. 50 (2004) 261-266
57. Shimizu M., Sjoquist P.O., Wang Q.D., and Ryden L. Effects of the angiotensin AT1 receptor blocker candesartan on myocardial ischemic/reperfusion injury. J. Am. Soc. Nephrol. 10 Suppl 11 (1999) S137-S142
58. Taku S., Hiroyuk K., Masaya O., Hidehiko S., Tomoya O., and Kazuo M. Candesartan reduces superoxide production after global cerebral ischemia. NeuroReport 16 4 (2005) 325-328 15 March
59. Titus T., Badet L., and Gray D.W. Islet cell transplantation for insulin-dependant diabetes mellitus: perspectives from the present and prospects for the future. Expert Rev. Mol. Med. 6 2 (2000) 1-28
60. Toni D., De Michele M., Fiorelli M., Bastianello S., Camerlingo M., Sacchetti M.L., Argentino C., and Fieschi C. Influence of hyperglycemia on infarct size and clinical outcome of acute ischemic stroke patients with intracranial arterial occlusion. J. Neurol. Sci. 123 (1994) 129-133
61. Touyz R.M., and Schiffrin E.L. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J. Hypertens. 19 (2001) 1245-1254
62. Traub O., and Van Bibber R. Role of nitric oxide in insulin-dependent diabetes mellitus-related vascular complications. West. J. Med. 162 5 (1995) 439-445
63. Uchiyama M., and Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 86 (1978) 271-278
64. Wei J., and Quast M.J. Effect of nitric oxide synthase inhibitor on a hyperglycemic rat model of reversible focal ischemia: detection of excitatory amino acids release and hydroxyl radical formation. Brain Res. 791 (1998) 146-156
65. Williams L.S., Rotich J., Qi R., Fineberg N., Espay A., Bruno A., Fineberg S.E., and Tierney W.R. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 59 (2002) 67-71
66. Wolf G. Free radical production and angiotensin. Curr. Hypertens. Rep. 2 (2000) 167-173
67. Yorek M.A. The role of oxidative stress in diabetic vascular and neural disease. Free Radic. Res. 37 (2003) 471-480